June 4, 2009 — The latest results from the European First Episode Schizophrenia Trial (EUFEST) show that when it comes to improving cognition in patients with schizophrenia, there is little difference ...

SCOTTSDALE, Arizona ― Second-generation antipsychotics (SGAs) differ with regard to efficacy and side effect profiles for the treatment of first-episode psychosis, according to the results of a new ...

Panelists discuss how thoughtful sequencing of antipsychotics enhances adherence, safety, and long-term efficacy. Panelists discuss how first-generation antipsychotics primarily manage positive ...

Schizophrenia medication falls under two main categories: older, first-generation, or "typical" antipsychotics and newer drugs for schizophrenia known as second-generation or "atypical" antipsychotics ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

Analysis from a Columbia and Rutgers Health team finds long-term antipsychotic use rose 65% from 2015 to 2024.

Patients on antipsychotics need to be regularly monitored for signs of tardive dyskinesia, a medication-induced movement disorder diagnosed when the involuntary movements persist for at least a month ...

—That question formed the basis of a new study from the U.K., which sought to learn more about the risk of tardive dyskinesia (TD)—a persistent, potentially irreversible movement disorder—in children ...